Sign Out
Psychiatric disorders: Anxiety.
Nervous system disorders: Taste alteration, headache, dizziness, convulsions, paraesthesia, tremor, somnolence, transient parosmia.
Eye disorders: Visual disturbance.
Cardiac disorders: Tachycardia.
Respiratory, thoracic and mediastinal disorders: Dyspnoea, coughing, bronchospasm, respiratory distress, throat irritation, sneezing.
Vascular disorders: Flushing.
Gastrointestinal disorders: Nausea, vomiting, diarrhea.
Skin and subcutaneous tissue disorders: Nephrogenic systemic fibrosis (NSF), pruritus, face oedema, angioedema, urticaria, rash, skin plaque*.
Musculoskeletal and connective tissue disorders: Arthralgia.
Renal and urinary system disorders: In patients with pre-existing severe renal insufficiency: Acute kidney injury, increase in blood creatinine.
General disorders and administration site conditions: Feeling hot, injection site pain, chest pain, fever, shivering.
* Cases of gadolinium associated skin plaques with demonstrated sclerotic bodies on histology have been reported with gadodiamide in patients who do not otherwise have symptoms or signs of nephrogenic systemic fibrosis.
View ADR Reporting Link
Continue with Google